Head to Head Contrast: InterCure (NASDAQ:INCR) and Varex Imaging (NASDAQ:VREX)

Varex Imaging (NASDAQ:VREX) and InterCure (NASDAQ:INCR) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.

Risk and Volatility

Varex Imaging has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, InterCure has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.

Insider and Institutional Ownership

8.3% of InterCure shares are owned by institutional investors. 4.3% of Varex Imaging shares are owned by insiders. Comparatively, 0.2% of InterCure shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Varex Imaging and InterCure’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Varex Imaging	-8.32%	7.19%	3.06%
InterCure	N/A	N/A	N/A

Earnings and Valuation

This table compares Varex Imaging and InterCure”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Varex Imaging	$844.60 million	0.61	-$70.30 million	($1.70)	-7.23
InterCure	$64.55 million	N/A	-$18.32 million	$0.13	10.42

InterCure has lower revenue, but higher earnings than Varex Imaging. Varex Imaging is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and target prices for Varex Imaging and InterCure, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Varex Imaging	1	0	2	0	2.33
InterCure	1	0	0	0	1.00

Varex Imaging presently has a consensus price target of $17.00, indicating a potential upside of 38.28%. Given Varex Imaging’s stronger consensus rating and higher probable upside, research analysts plainly believe Varex Imaging is more favorable than InterCure.

Summary

Varex Imaging beats InterCure on 7 of the 13 factors compared between the two stocks.

About Varex Imaging

Varex Imaging Corporation designs, manufactures, and sells X-ray imaging components. The company operates through two segments, Medical and Industrial. The Medical segment designs, manufactures, sells, and services X-ray imaging components, comprising X-ray tubes, digital detectors and accessories, ionization chambers, high voltage connectors, image-processing software and workstations, 3D reconstruction software, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, and heat exchangers. This segment's products are used in a range of applications, including CT, mammography, oncology, cardiac, surgery, dental, and other diagnostic radiography uses. The Industrial segment designs, develops, manufactures, sells, and services Linatron X-ray linear accelerators, X-ray tubes, digital detectors, high voltage connectors, and coolers for use in security and inspection applications, such as baggage screening at airports, cargo screening at ports and borders, and nondestructive testing, irradiation, and inspection in various applications. The company sells its products through imaging system original equipment manufacturers, independent service companies, and distributors, as well as directly to end-users. It has operations in North America, South America, Europe, Russia, the Middle East, India, Africa, Asia, and Australia. Varex Imaging Corporation was incorporated in 2016 and is headquartered in Salt Lake City, Utah.

About InterCure

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.